ATE435238T1 - Herstellung eines einkettigen fv antikörperfragments - Google Patents

Herstellung eines einkettigen fv antikörperfragments

Info

Publication number
ATE435238T1
ATE435238T1 AT04010702T AT04010702T ATE435238T1 AT E435238 T1 ATE435238 T1 AT E435238T1 AT 04010702 T AT04010702 T AT 04010702T AT 04010702 T AT04010702 T AT 04010702T AT E435238 T1 ATE435238 T1 AT E435238T1
Authority
AT
Austria
Prior art keywords
preparation
antibody fragment
single chain
methods
antibody fragments
Prior art date
Application number
AT04010702T
Other languages
English (en)
Inventor
Tobias Raum
Julia Henckel
Eva Krinner
Silke Mittelstrass
Andreas Wolf
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Application granted granted Critical
Publication of ATE435238T1 publication Critical patent/ATE435238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04010702T 2004-05-05 2004-05-05 Herstellung eines einkettigen fv antikörperfragments ATE435238T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04010702A EP1593690B1 (de) 2004-05-05 2004-05-05 Herstellung eines einkettigen fv Antikörperfragments

Publications (1)

Publication Number Publication Date
ATE435238T1 true ATE435238T1 (de) 2009-07-15

Family

ID=34924877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04010702T ATE435238T1 (de) 2004-05-05 2004-05-05 Herstellung eines einkettigen fv antikörperfragments

Country Status (8)

Country Link
US (2) US8247194B2 (de)
EP (2) EP1593690B1 (de)
AT (1) ATE435238T1 (de)
AU (1) AU2005238203B2 (de)
CA (1) CA2562604C (de)
DE (1) DE602004021773D1 (de)
DK (1) DK1593690T3 (de)
WO (1) WO2005105844A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE435238T1 (de) * 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
SI1874819T1 (sl) * 2005-04-18 2015-09-30 Amgen Research (Munich) Gmbh Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov
RS63382B1 (sr) 2005-05-18 2022-08-31 Morphosys Ag Anti-gm-csf antitela i njihova upotreba
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR20090088950A (ko) * 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2215119B1 (de) 2007-11-13 2012-12-26 Evec Inc. An hgm-csf bindende monoklonale antikörper und medizinische zusammensetzungen damit
US8840890B2 (en) * 2008-11-12 2014-09-23 University Of Maryland, Baltimore Rapid expression cloning of human monoclonal antibodies from memory B cells
RU2712273C2 (ru) 2008-12-22 2020-01-28 Де Юниверсити Оф Мельбурн Лечение остеоартрита
RU2712166C2 (ru) 2008-12-22 2020-01-24 Де Юниверсити Оф Мельбурн Лечение боли
CN102782149B (zh) 2009-11-04 2014-11-12 默沙东公司 经工程改造的抗-tslp抗体
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
KR20240090993A (ko) 2013-08-30 2024-06-21 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
CA2895659A1 (en) 2014-07-01 2016-01-01 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
AU2017415310B2 (en) * 2017-05-25 2023-08-03 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE435238T1 (de) * 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments

Also Published As

Publication number Publication date
CA2562604A1 (en) 2005-11-10
EP1742967A2 (de) 2007-01-17
CA2562604C (en) 2014-02-18
DK1593690T3 (da) 2009-11-09
AU2005238203B2 (en) 2010-09-02
US20130171165A1 (en) 2013-07-04
WO2005105844A2 (en) 2005-11-10
AU2005238203A1 (en) 2005-11-10
US9279017B2 (en) 2016-03-08
US20080193978A1 (en) 2008-08-14
EP1593690B1 (de) 2009-07-01
EP1593690A1 (de) 2005-11-09
US8247194B2 (en) 2012-08-21
DE602004021773D1 (de) 2009-08-13
WO2005105844A3 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE435238T1 (de) Herstellung eines einkettigen fv antikörperfragments
NL300911I2 (nl) sarilumab
WO2008097817A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
NO2017032I1 (no) bezlotoksumab
DE602005018325D1 (de) Antikörper mit korrigierten cdr
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
NZ607711A (en) Antibodies directed to her-3 and uses thereof
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
WO2009112245A9 (en) Antibody against the csf-1 r
WO2008027236A3 (en) Multispecific antibodies
WO2011117648A3 (en) Disulfide stabilised antibodies and fragments thereof
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
WO2010027488A3 (en) Monoclonal antibodies
WO2011112850A3 (en) Humanized and chimeric anti-properdin antibodies
NZ594668A (en) Humanised antibodies with anti-tumour activity
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
NZ607881A (en) Humanized antibody against amyloid beta
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
BRPI0509495A2 (pt) anticorpo humanizado
NZ708488A (en) Method of providing disease-specific binding molecules and targets

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1593690

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1593690

Country of ref document: EP